informcll registry analysis: ibrutinib vs chemoimmunotherapy for the first-line treatment of cll/sll
Published 1 year ago • 62 plays • Length 5:59Download video MP4
Download video MP3
Similar videos
-
4:29
first-line ibrutinib vs chemoimmunotherapy in cll: a real-world data analysis
-
1:56
ibrutinib plus venetoclax for first-line treatment of cll: 4-year follow-up data
-
1:05
final analysis of the alpine trial: zanubrutinib vs ibrutinib in r/r cll
-
2:39
the safety and efficacy of ibrutinib for the treatment of cll
-
17:23
updates in cll: key clinical trials in the frontline and r/r setting, pre-clinical data and mrd
-
2:47
cc-99282 ± rituximab for r/r nhl: phase i/ii trial interim analysis
-
6:48
patient selection for treatment with ibrutinib in cll
-
3:46
the characteristics and mode of action of ibrutinib for cll
-
4:31
sequence of administration of ibrutinib with obinutuzumab in r/r cll patients
-
4:58
overview of the toxicities associated with bispecific agents in multiple myeloma
-
1:28
overview of resonate-2 clinical trial of ibrutinib in cll
-
2:57
the cll12 trial of ibrutinib in early stage cll
-
1:31
can ibrutinib be used as a first-line treatment in cll?
-
2:09
real-world incidence of ibrutinib-related cardiotoxicity in cll: insights from the lls registry
-
4:08
phase ib trial of ianalumab plus ibrutinib for cll
-
3:26
informcll: a prospective observational registry
-
6:05
real-world data on the effect of ibrutinib flexible dosing treatment strategies on ttnt in cll/sll
-
1:11
patient selection in the treatment of cll
-
2:55
clinical outcomes of patients with cll receiving long-term ibrutinib in the resonate-2 study
-
5:52
understanding ultra high-risk cll and advances with ibrutinib therapy
-
2:51
key btk inhibitor trials for the initial treatment of cll